MILWAUKEE, June 10, 2026 /PRNewswire/ — Ademi LLP is investigating Nuvalent (NASDAQ: NUVL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.
Nuvalent stockholders will receive $124 per share and the aggregate equity value of the transaction is approximately $10.6 billion. Nuvalent insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Nuvalent by imposing a significant penalty if Nuvalent accepts a competing bid. We are investigating the conduct of the Nuvalent board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-nuvalent-inc-is-obtaining-a-fair-price-for-public-shareholders-302796643.html
SOURCE Ademi LLP
